188Re-Lanreotide: Determination of radiopharmacokinetics parameters in rats

2^nd World Congress on Biomarkers & Clinical Research

12-14 September 2011 Baltimore, USA

Eva M. Molina-Trinidad, Consuelo Arteaga de Murphy, Helgi Jung-Cook, Eduardo Murphy Stack, Martha Pedraza- López, José Luis Morales- Márquez, Guadalupe Vertiz Serrano

Posters: J Mol Biomark Diagn

Abstract :

Background: We used 188Re-lanreotide to determine its radiopharmaceutical parameters in a model of Wistar rats with induced hepatocellular carcinoma, aft er a single intravenous dose. Th e rat model is useful to determine the pharmacokinetic parameters and the tumor/organ ratios of 188Re-lanreotide to be used for calculating the personal dose following the methodology MIRDOSE and later in the diagnosis and therapy of cancer. Objetive: We used 188Re-lanreotide to determine radiopharmaceutical parameters in a model in rats Wistar. Methods: 188Re labeled by a modifi ed direct method. AS-30D hepatoma cells were obtained from ascites of a Wistar rat with hepatoma. Healthy and tumor induced hepatocellular carcinoma Wistar rats were used for distribution and radiopharmacokinetic studies. 188Re-lanreotide, ≈1.8 MBq in 0.1 mL was injected in the peritoneal cavity and in the dorsal left side of healthy rats. Th e rats were sacrifi ced at 0.083, 0.25, 0.5, 1.16, 3 and 24 h post injection. Th e activity (%IA/g) of all the blood samples in the following times: 0.25, 0.5, 1.1, 3, 5, 8, 12, 15, 18, and 24 h for healthy rats and 0.25, 0.5, 1.16, 3, and 24 h for hepatoma induced rats. Results: Th e radiopharmacokinetic parameters were calculated following a two-compartment, fi rst-order elimination model of 188Re-lanreotide in healthy rats and for rats with induced tumor using the WinNonlin program. Conclusion: A pharmacokinetic profi le of 188Re-lanreotide in healthy and hepatoma tumor induced rats follow model two-compartment. With mean residence time and the mean half life we will be calculate the therapeutic dose following MIRDOSE methodology